A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease

Journal of the American Medical Directors Association

Volumn 17, Issue 2, 2016, Pages 142-147

  Herrmann, Nathan ^a,b,c   O'Regan, Jordana ^d   Ruthirakuhan, Myuri ^b   Kiss, Alexander ^b   Eryavec, Goran ^c   Williams, Evelyn ^a   Lanctôt, Krista L ^a,b,d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b Canada   (Canada)

^c NORTH YORK GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer disease; Cholinesterase inhibitors; Institutionalization; Neuropsychiatric symptoms; Randomized controlled trial

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ADVERSE OUTCOME; AGED; ALZHEIMER DISEASE; APPETITE DISORDER; ARTICLE; ATRIAL FIBRILLATION; BEHAVIOR DISORDER; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION SCALE; CONFUSION; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DELUSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HALLUCINATION; HUMAN; INTESTINE OBSTRUCTION; MALE; MENTAL DISEASE ASSESSMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHIATRIC INVENTORY NURSING HOME; OUTCOME ASSESSMENT; PERINEUM INJURY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFECTION; SEIZURE; SIDE EFFECT; THRUSH; TREATMENT WITHDRAWAL; VOMITING; WEIGHT REDUCTION; NURSING HOME; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NURSING HOMES; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX;

EID: 84959136000     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2015.08.019     Document Type: Article

References (38)

1. Prince M., Bryce R., Albanese E., et al. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 2013, 9:63-75 e2.
2. Herrmann N., Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe alzheimer disease. CMAJ 2008, 179:1279-1287.
3. Canadian study of health and aging Study methods and prevalence of dementia. CMAJ 1994, 150:899-913.
4. Dementia: A NICE-SCIE guideline on supporting People with dementia and their Carers in health and Social care 2007, National Collaborating Centre for Mental Health (UK), British Psychological Society, Leicester (UK).
5. Herrmann N., Lanctot K.L., Hogan D.B. Pharmacological recommendations for the symptomatic treatment of dementia: The Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther 2013, 5:S5.
6. Moore A., Patterson C., Lee L., et al. Fourth Canadian Consensus Conference on the Diagnosis and treatment of Dementia: Recommendations for family physicians. Can Fam Physician 2014, 60:433-438.
7. Howard R., McShane R., Lindesay J., et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012, 366:893-903.
8. Homma A., Imai Y., Tago H., et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008, 25:399-407.
9. Black S.E., Doody R., Li H., et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007, 69:459-469.
10. Feldman H., Gauthier S., Hecker J., et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001, 57:613-620.
11. Leon-Salas B., Olazaran J., Cruz-Orduna I., et al. Quality of life (QoL) in community-dwelling and institutionalized Alzheimer's disease (AD) patients. Arch Gerontol Geriatr 2013, 57:257-262.
12. Wattmo C., Wallin A.K., Londos E., et al. Risk factors for nursing home placement in Alzheimer's disease: A longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist 2011, 51:17-27.
13. Smith G.E., Kokmen E., O'Brien P.C. Risk factors for nursing home placement in a population-based dementia cohort. J Am Geriatr Soc 2000, 48:519-525.
14. Hansdottir H., Gudmannssson P.G. [Medication use in nursing homes in Iceland 2002-2004. A descriptive study.]. Laeknabladid 2013, 99:383-389.
15. Vetrano D.L., Tosato M., Colloca G., et al. Polypharmacy in nursing home residents with severe cognitive impairment: Results from the SHELTER Study. Alzheimers Dement 2013, 9:587-593.
16. Herrmann N., Gill S.S., Bell C.M., et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007, 55:1517-1523.
17. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006, 1:CD005593.
18. Lanctot K.L., Herrmann N., Yau K.K., et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A meta-analysis. CMAJ 2003, 169:557-564.
19. Gill S.S., Anderson G.M., Fischer H.D., et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study. Arch Intern Med 2009, 169:867-873.
20. Lopez O.L., Becker J.T., Saxton J., et al. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005, 53:83-87.
21. Iverson G.L., Hopp G.A., DeWolfe K., et al. Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version. Int J Geriatr Psychiatry 2002, 17:438-443.
22. Guy W. CGI:Clinical global impressions. ECDEU Assessment manual for psychopharmacology 1976, 218-222. US Department of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch, Rockville, MD. W. Guy (Ed.).
23. Schneider L.S., Olin J.T., Doody R.S., et al. Validity and reliability of the Alzheimer's disease cooperative Study-Clinical global impression of change. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord 1997, 11. S22-S32.
24. Winblad B., Kilander L., Eriksson S., et al. Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet 2006, 367:1057-1065.
25. Workgroup A.G.S.C.W. American Geriatrics Society identifies another five things that healthcare providers and patients should question. J Am Geriatr Soc 2014, 62:950-960.
26. O'Regan J., Lanctôt K.L., Mazereeuw G., Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. J Clin Psychiatr 2015, 76:e1424-e1431.
27. Holmes H.M., Hayley D.C., Alexander G.C., et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006, 166:605-609.
28. Tjia J., Rothman M.R., Kiely D.K., et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc 2010, 58:880-888.
29. Pinto T., Lanctot K.L., Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. Ageing Res Rev 2011, 10:404-412.
30. Holmes C., Wilkinson D., Dean C., et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004, 63:214-219.
31. Howard R.J., Juszczak E., Ballard C.G., et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007, 357:1382-1392.
32. Johannsen P., Salmon E., Hampel H., et al. Assessing therapeutic efficacy in a progressive disease: A study of donepezil in Alzheimer's disease. CNS Drugs 2006, 20:311-325.
33. Cummings J.L., McRae T., Zhang R., et al. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006, 14:605-612.
34. Herrmann N., Rabheru K., Wang J., et al. Galantamine treatment of problematic behavior in alzheimer disease: Post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005, 13:527-534.
35. Cummings J.L., Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998, 6. S64-S78.
36. Cohen D., Eisdorfer C., Gorelick P., et al. Sex differences in the psychiatric manifestations of Alzheimer's disease. J Am Geriatr Soc 1993, 41:229-232.
37. Jost B.C., Grossberg G.T. The evolution of psychiatric symptoms in Alzheimer's disease: A natural history study. J Am Geriatr Soc 1996, 44:1078-1081.
38. Kowal K. Prevalence of serum specific antibodies to Borrelia burgdorferi antigens in persons from region of high risk of tick bites. Pneumonol Alergol Pol 1992, 60:67-70.